LAB (Standard BioTools) Other Stockholders Equity : $0.0 Mil (As of Dec. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Standard BioTools Other Stockholders Equity?

Standard BioTools's Other Stockholders Equity for the quarter that ended in Dec. 2024 was $0.0 Mil.

Standard BioTools's quarterly Other Stockholders Equity declined from Jun. 2024 ($0.0 Mil) to Sep. 2024 ($-0.0 Mil) but then increased from Sep. 2024 ($-0.0 Mil) to Dec. 2024 ($0.0 Mil).

Standard BioTools's annual Other Stockholders Equity increased from Dec. 2022 ($-0.0 Mil) to Dec. 2023 ($-0.0 Mil) and increased from Dec. 2023 ($-0.0 Mil) to Dec. 2024 ($0.0 Mil).

Standard BioTools Other Stockholders Equity Historical Data

The historical data trend for Standard BioTools's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Standard BioTools Other Stockholders Equity Chart

Standard BioTools Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Stockholders Equity

Get a 7-Day Free Trial

Standard BioTools Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Stockholders Equity	Get a 7-Day Free Trial															-	-	-	-	-

Standard BioTools Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

Standard BioTools Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Standard BioTools's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Standard BioTools Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Standard BioTools Inc (NAS:LAB) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

FLB:Germany

Address

2 Tower Place, Suite 2000, South San Francisco, CA, USA, 94080

Website

https://www.standardbio.com

Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.

Executives

Casdin Partners Master Fund, L.p.	director, 10 percent owner	WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Martin D Madaus	director	290 CONCORD ROAD, BILLERICA MA 01821
Jeffrey G. Black	officer: SVP & Chief Financial Officer	4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Eli Casdin	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Partners Fo1-msv, Lp	director	C/O CASDIN PARTNERS GP, LLC, 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Private Growth Equity Fund Ii Gp, Llc	director	1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Partners Gp, Llc	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Capital, Llc	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Private Growth Equity Fund Ii, L.p.	director	1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Fenel M Eloi	director	C/O INTERLEUKIN GENETICS INC, 135 BEAVER STREET, WALTHAM MA 02452
Caligan Partners Lp	10 percent owner	515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Frank Witney	director	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Jeremy Steven Davis	officer: SVP Chief Commercial Officer	C/O FLUIDIGM CORPORATION, 2 TOWER PLACE, SUITE 2000, SOUTH SAN FRANCISCO CA 94080
Hanjoon Alex Kim	officer: Chief Operating Officer	C/O FLUIDIGM CORPORATION, 2 TOWER PLACE, SUITE 2000, SOUTH SAN FRANCISCO CA 94080
Michael Egholm	director, officer: President & CEO	1 FRANKLIN STREET, UNIT 3104, BOSTON MA 02110